Lyell Immunopharma, Inc.

Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.

LYEL | US

Overview

Corporate Details

ISIN(s):: US55083R1041
LEI:
Country:: United States of America
Address:: 201 HASKINS WAY, 94080 SOUTH SAN FRANCISCO
Website:: https://lyell.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Lyell Immunopharma, Inc. is a clinical-stage T-cell reprogramming company focused on developing transformative Chimeric Antigen Receptor (CAR) T-cell therapies for patients with solid tumors and hematologic malignancies. The company's scientific platform is designed to overcome key barriers to successful cell therapy, such as T-cell exhaustion, to generate more durable and effective treatments. Lyell is advancing a pipeline of next-generation product candidates targeting cancers with significant unmet medical need. A lead candidate, rondecabtagene autoleucel (ronde-cel), is a dual-targeting CD19/CD20 therapy being evaluated in clinical trials for aggressive large B-cell lymphoma.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Lyell Immunopharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Lyell Immunopharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Lyell Immunopharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Humacyte, Inc. Bioengineering off-the-shelf human tissues for vascular repair and regenerative medicine.	United States of America	HUMA
Human Stem Cells Institute PJSC A biotech investor developing gene therapy, regenerative medicine, and genetic services.	Russian Federation	ISKJ
HUMASIS CO., LTD. Develops & manufactures rapid in-vitro diagnostic test kits & instruments for global POCT markets.	South Korea	205470
Humedix Co., Ltd. Develops hyaluronic acid-based pharma, aesthetics, medical devices, and offers CMO services.	South Korea	200670
HUONS CO., LTD. Global healthcare company providing pharmaceuticals, medical devices, and wellness products.	South Korea	243070
Huons Global Co., Ltd. Develops pharmaceuticals, medical devices, cosmetics, and health foods for the global market.	South Korea	084110
Hutchmed (China) Limited	Hong Kong	HCM
HUTCHMED (China) Ltd Develops and commercializes targeted therapies for cancer and immunological diseases worldwide.	United States of America	HCM
HWAIL PHARM. CO., LTD Develops and manufactures APIs, finished drugs, and functional ingredients for healthcare.	South Korea	061250
Hyloris Pharmaceuticals SA A biopharma company optimizing existing drugs for unmet needs via abbreviated pathways.	Belgium	HYL